X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
Details:
GEN will manufacture Mytesi (crofelemer) finished product and market the drug for HIV-related diarrhea in Turkey and eight neighboring countries following GEN's receipt of regulatory approval for crofelemer for these indications in these countries.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: GEN
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 20, 2024
Details:
Crofelemer is a plant-based drug extracted & purified from the red bark sap. It is being developed for relief and treatment of moderate-to-severe diarrhea, with or without concomitant antimicrobial therapy from bacterial, viral & parasitic infections including Vibrio cholerae.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
Mytesi (crofelemer) is a CFTR/CaCC inhibitor small molecule drug administered orally as a delayed release tablet, for prophylaxis of diarrhea in cancer patients.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2023
Details:
Under the agreement, Napo grants Quadri Pharma exclusive promotional, commercialization, and distribution rights for a powder formulation of Mytesi (crofelemer), the only oral FDA-approved prescription drug under botanical guidance, for oral solution.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Quadri Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 02, 2023
Details:
Mytesi (crofelemer) powder for oral solution inhibits both cAMP-stimulated CFTR chloride ion channel and the CaCC at the luminal membrane of enterocytes, which being investigated for the treatment of microvillus inclusion disease.
Lead Product(s): Crofelemer
Therapeutic Area: Genetic Disease Product Name: Mytesi
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 09, 2023
Details:
Mytesi (crofelemer) powder for oral solution inhibits both cAMP-stimulated CFTR chloride ion channel and the CaCC at the luminal membrane of enterocytes, which being investigated for the treatment of short bowel syndrome.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2023
Details:
Mytesi (crofelemer) powder for oral solution inhibits both cAMP-stimulated CFTR chloride ion channel and the CaCC at the luminal membrane of enterocytes, which being investigated for the treatment of microvillus inclusion disease.
Lead Product(s): Crofelemer
Therapeutic Area: Genetic Disease Product Name: Mytesi
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Napo Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
Mytesi (crofelemer) inhibits both cAMP-stimulated CFTR chloride ion channel and the CaCC at the luminal membrane of enterocytes. Drug blocks Cl¯ secretion and accompanying high volume water loss in diarrhea, normalizing Cl¯ flow and water in the gastrointestinal tract.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
Mytesi (crofelemer) is an inhibits both cAMP-stimulated CFTR chloride ion channel, and the CaCC at the luminal membrane of enterocytes. Drug blocks Cl¯ secretion and accompanying high volume water loss in diarrhea, normalizing Cl¯ flow and water in the gastrointestinal tract.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
Mytesi (crofelemer) inhibits both cAMP-stimulated CFTR chloride ion channel and the CaCC at the luminal membrane of enterocytes. Drug blocks Cl¯ secretion and accompanying high volume water loss in diarrhea, normalizing Cl¯ flow and water in the gastrointestinal tract.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2023
Details:
Mytesi (crofelemer) is an inhibits both cAMP-stimulated CFTR chloride ion channel, and the CaCC at the luminal membrane of enterocytes. Drug blocks Cl¯ secretion and accompanying high volume water loss in diarrhea, normalizing Cl¯ flow and water in the gastrointestinal tract.
Lead Product(s): Crofelemer
Therapeutic Area: Genetic Disease Product Name: Mytesi
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
Mytesi (crofelemer) is an inhibits both cAMP-stimulated CFTR chloride ion channel, and the CaCC at the luminal membrane of enterocytes. Drug blocks Cl¯ secretion and accompanying high volume water loss in diarrhea, normalizing Cl¯ flow and water in the gastrointestinal tract.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2023
Details:
Mytesi (crofelemer) is an inhibits both cAMP-stimulated CFTR chloride ion channel, and the CaCC at the luminal membrane of enterocytes. Drug blocks Cl¯ secretion and accompanying high volume water loss in diarrhea, normalizing Cl¯ flow and water in the gastrointestinal tract.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
The company's initial focus is on clinical development and future registration in Europe of Mytesi (crofelemer) for two debilitating rare disease target indications: short bowel syndrome (SBS) and congenital diarrheal disorders (CDD) with intestinal failure.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: SPRIM Global Investments
Deal Size: $58.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement February 09, 2023
Details:
Mytesi (crofelemer) is an inhibits both cAMP-stimulated CFTR chloride ion channel, and the CaCC at the luminal membrane of enterocytes. Drug blocks Cl¯ secretion and accompanying high volume water loss in diarrhea, normalizing Cl¯ flow and water in the gastrointestinal tract.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Details:
Mytesi (crofelemer) is an inhibits both cAMP-stimulated CFTR chloride ion channel, and the CaCC at the luminal membrane of enterocytes. Drug blocks Cl¯ secretion and accompanying high volume water loss in diarrhea, normalizing Cl¯ flow and water in the gastrointestinal tract.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
Mytesi (crofelemer), is a novel, oral plant-based medicine purified from the red bark sap, also referred to as "dragon's blood," of the medicinal Croton lechleri tree in the Amazon Rainforest.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
Mytesi (crofelemer) is a novel, oral plant-based medicine purified from the red bark sap. Crofelemer is currently being evaluated in a prophylactic setting in adult patients with solid tumors receiving targeted therapy.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
Mytesi (crofelemer) is an antidiarrheal indicated in the U.S. for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea.
Lead Product(s): Crofelemer
Therapeutic Area: Genetic Disease Product Name: Mytesi
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Napo Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
Mytesi (crofelemer) is a botanical (plant-based) drug extracted and purified from the red bark sap, also referred to as "dragon's blood," of the medicinal Croton lechleri tree.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2022
Details:
Mytesi, only oral plant-based prescription medicine approved under FDA Botanical Guidance, is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Napo EU
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Agreement March 09, 2021
Details:
Jaguar intends to use the proceeds to support regulatory activities associated with the Company's development pipeline, including funding continued patient enrollment for the pivotal Phase 3 trial of Mytesi for prophylaxis of diarrhea in adult cancer patients.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 23, 2020
Details:
Proceeds will be allocated to support regulatory activities associated with the company's development pipeline, including funding the pivotal clinical trial for mytesi for cancer therapy-related diarrhea (ctd).
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 01, 2020
Details:
Oasis agreed to purchase additional accounts receivable of the Company related to the sales of the Company's Mytesi® drug product to Cardinal Health for the period of August 11, 2020 through September 3, 2020.
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oasis Capital
Deal Size: $2.3 million Upfront Cash: Undisclosed
Deal Type: Agreement September 10, 2020
Details:
U.S. Food and Drug Administration (FDA) for the use of crofelemer (Mytesi®) for prophylaxis and symptomatic relief of diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy ("cancer therapy‑related diarrhea" (CTD)).
Lead Product(s): Crofelemer
Therapeutic Area: Gastroenterology Product Name: Mytesi
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
Jaguar Health and Napo Pharmaceuticals have jointly entered into an accounts receivable purchase deal with Oasis Capital pursuant to which Oasis has initially agreed to purchase all of the Company's accounts receivable related to the April 2020 sales of Mytesi drug product.
Lead Product(s): Crofelemer
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oasis Capital
Deal Size: $2.7 million Upfront Cash: Undisclosed
Deal Type: Agreement May 13, 2020
Details:
Transaction Proceeds Will be Allocated to Support Advancement of Regulatory Activities Associated with Jaguar's Pipeline, Including the Company's Lead Product Candidate, Crofelemer.
Lead Product(s): Crofelemer
Therapeutic Area: Infections and Infectious Diseases Product Name: Mytesi
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Iliad Research and Trading
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Agreement March 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
